BR112016009047A2 - Uso de moléculas de ligação à semaforina-4d para tratar transtornos neurodegenerativos - Google Patents

Uso de moléculas de ligação à semaforina-4d para tratar transtornos neurodegenerativos

Info

Publication number
BR112016009047A2
BR112016009047A2 BR112016009047A BR112016009047A BR112016009047A2 BR 112016009047 A2 BR112016009047 A2 BR 112016009047A2 BR 112016009047 A BR112016009047 A BR 112016009047A BR 112016009047 A BR112016009047 A BR 112016009047A BR 112016009047 A2 BR112016009047 A2 BR 112016009047A2
Authority
BR
Brazil
Prior art keywords
semaphorin
binding molecules
neurodegenerative disorders
treat neurodegenerative
plexin
Prior art date
Application number
BR112016009047A
Other languages
English (en)
Other versions
BR112016009047B1 (pt
Inventor
S Smith Ernest
Zauderer Maurice
J Bowers William
Jonason Alan
Original Assignee
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccinex Inc filed Critical Vaccinex Inc
Publication of BR112016009047A2 publication Critical patent/BR112016009047A2/pt
Publication of BR112016009047B1 publication Critical patent/BR112016009047B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

USO DE MOLÉCULAS DE LIGAÇÃO À SEMAFORINA-4D PARA TRATAR TRANSTORNOS NEURODEGENERATIVOS. Métodos para aliviar sintomas em um sujeito que apresenta um transtorno neurodegenerativo, compreendendo administrar ao sujeito uma quantidade eficaz de uma molécula de ligação isolada que se liga especificamente à semaforina-4D (SEMA4D) ou aos seus receptores de Plexina-B1 ou Plexina-B2, são fornecidos neste relatório.
BR112016009047-0A 2013-10-21 2014-10-21 Uso de uma quantidade eficaz de um anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga especificamente à semaforina-4d para aliviar os sintomas em um indivíduo que possui doença de huntington BR112016009047B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361893814P 2013-10-21 2013-10-21
US61/893.814 2013-10-21
US201461979384P 2014-04-14 2014-04-14
US61/979.384 2014-04-14
US201462012805P 2014-06-16 2014-06-16
US62/012.805 2014-06-16
PCT/US2014/061592 WO2015061330A1 (en) 2013-10-21 2014-10-21 Use of semaphorin-4d binding molecules for treating neurodegenerative disorders

Publications (2)

Publication Number Publication Date
BR112016009047A2 true BR112016009047A2 (pt) 2017-09-19
BR112016009047B1 BR112016009047B1 (pt) 2024-02-06

Family

ID=52826380

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016009047-0A BR112016009047B1 (pt) 2013-10-21 2014-10-21 Uso de uma quantidade eficaz de um anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga especificamente à semaforina-4d para aliviar os sintomas em um indivíduo que possui doença de huntington

Country Status (19)

Country Link
US (4) US9598495B2 (pt)
EP (2) EP3639853A1 (pt)
JP (2) JP6461944B2 (pt)
KR (4) KR20230159633A (pt)
CN (2) CN116966293A (pt)
AU (3) AU2014340210B2 (pt)
BR (1) BR112016009047B1 (pt)
CA (2) CA2927841C (pt)
DK (1) DK3060252T3 (pt)
EA (1) EA033072B1 (pt)
ES (1) ES2773961T3 (pt)
IL (3) IL295045B2 (pt)
MX (2) MX2016005050A (pt)
NZ (1) NZ630892A (pt)
PL (1) PL3060252T3 (pt)
PT (1) PT3060252T (pt)
SG (2) SG10201707786QA (pt)
WO (1) WO2015061330A1 (pt)
ZA (1) ZA201602686B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6059013B2 (ja) 2009-05-08 2017-01-11 バクシネックス インコーポレーティッド 抗ｃｄ１００抗体およびこれを使用するための方法
SG11201401458UA (en) 2011-10-11 2014-07-30 Vaccinex Inc Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
WO2014116982A2 (en) * 2013-01-25 2014-07-31 Brandeis University Methods of modulating gabaergic inhibitory synapse formation and function
CA2916245C (en) 2013-06-25 2023-01-24 Vaccinex, Inc. Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
MX2018012818A (es) 2016-04-22 2019-07-04 Vaccinex Inc Presentacion de proteina de membrana integral en viriones envueltos extracelulares de poxvirus.
IL264343B2 (en) 2016-08-02 2024-05-01 Vaccinex Inc Improved methods for generating polynucleotide libraries in cowpox/eukaryotic cells
JP7084689B2 (ja) * 2016-12-08 2022-06-15 公益財団法人東京都医学総合研究所 脳組織の異常を伴う非ヒト動物の作製方法およびその利用
SG11201906670PA (en) * 2017-02-22 2019-08-27 Vaccinex Inc Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases
JP7159187B2 (ja) * 2017-03-20 2022-10-24 バクシネックス インコーポレーティッド セマフォリン－４ｄ抗体とエピジェネティック調節剤の組み合わせを用いたがんの処置方法
EP3618865A4 (en) 2017-05-05 2021-05-05 Vaccinex, Inc. 4D ANTI-SEMAPHORIN HUMAN ANTIBODY
CN109410218B (zh) * 2018-10-08 2020-08-11 百度在线网络技术（北京）有限公司 用于生成车辆损伤信息的方法和装置
EP3693380A1 (en) * 2019-02-11 2020-08-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Dual inhibition of plexin-b1 and plexin-b2
US11597765B2 (en) 2020-06-25 2023-03-07 Vaccinex, Inc. Use of semaphorin-4D binding molecules for the treatment of Rett syndrome
WO2022137964A1 (ja) * 2020-12-23 2022-06-30 国立大学法人大阪大学 軟骨・骨・関節疾患の予防または治療用医薬組成物および軟骨・骨・関節疾患の予防または治療用薬剤のスクリーニング方法
WO2023048726A1 (en) * 2021-09-27 2023-03-30 Vaccinex, Inc. Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders
US20230331863A1 (en) 2022-02-13 2023-10-19 Vaccinex, Inc. Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5070192A (en) 1988-03-23 1991-12-03 The Johns Hopkins University Cloned human topoisomerase i: cdna expression, and use for autoantibody detection
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6497872B1 (en) 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5639856A (en) 1993-09-13 1997-06-17 The Regents Of The University Of California Semaphorin gene family
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
ES2273415T3 (es) 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
AU6897998A (en) 1997-04-11 1998-11-11 Dendreon Corporation Composition and method for inducing an immune response against tumour-rela ted antigens
EP0892047A3 (de) 1997-07-09 2000-03-08 Hoechst Marion Roussel Deutschland GmbH Humanes und murines Semaphorin L
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6638501B1 (en) 1997-09-29 2003-10-28 Neurospheres Holdings Ltd. Use of multipotent neural stem cell progeny to augment non-neural tissues
US5958767A (en) 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
DE69839970D1 (de) 1998-11-10 2008-10-16 Univ Rochester Methoden zu herstellung von genbanken
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
JP3787473B2 (ja) 1999-11-30 2006-06-21 独立行政法人科学技術振興機構 セマフォリン受容体
WO2001046384A2 (en) 1999-12-23 2001-06-28 Cornell Research Foundation, Inc. A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells
US6635742B1 (en) 2000-01-25 2003-10-21 Nuvelo, Inc. Antibodies specific for semaphorin-like polypeptides
DE60233509D1 (de) 2001-06-20 2009-10-08 Fibron Ltd Fgfr3 blockierende antikörper, verfahren zum screening darauf und verwendungen davon
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1365018A1 (en) 2002-05-23 2003-11-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) CD100 semaphorin in myelination
AU2003232456B2 (en) 2002-05-30 2009-06-04 Macrogenics, Inc. CD16A binding proteins and use for the treatment of immune disorders
EP1442749A1 (en) 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
CA2526085A1 (en) 2003-05-30 2005-01-06 Genentech, Inc. Treatment with anti-vegf antibodies
EP2336178A1 (en) 2003-12-11 2011-06-22 Genentech, Inc. Methods and compositions for inhibiting C-Met dimerization and activation
DK1773885T3 (da) 2004-08-05 2010-08-16 Genentech Inc Humaniserede anti-c-met-antagonister
US20060147449A1 (en) * 2004-11-15 2006-07-06 Brass Lawrence F Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses
AU2006235271B2 (en) 2005-04-07 2011-05-19 Novartis Vaccines And Diagnostics Inc. SEMA4D in cancer diagnosis, detection and treatment
JP2007308465A (ja) 2006-05-15 2007-11-29 Boehringer Ingelheim Internatl Gmbh 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法
US7919594B2 (en) 2007-02-14 2011-04-05 Vaccinex, Inc. Human anti-CD100 antibodies
TW200934512A (en) 2008-01-10 2009-08-16 Genentech Inc PLEXIND1 agonists and their use
JP6059013B2 (ja) 2009-05-08 2017-01-11 バクシネックス インコーポレーティッド 抗ｃｄ１００抗体およびこれを使用するための方法
JP5797190B2 (ja) 2009-05-15 2015-10-21 アイ アール エックス セーラピューティクス， インコーポレイテッド ワクチン免疫療法
AU2011267869A1 (en) 2010-06-14 2013-01-10 Vaccinex, Inc. Anti-VEGF antibodies and uses thereof
JP5925768B2 (ja) 2011-05-13 2016-05-25 国立大学法人 東京医科歯科大学 骨形成促進剤
SG11201401458UA (en) * 2011-10-11 2014-07-30 Vaccinex Inc Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
CA2916245C (en) 2013-06-25 2023-01-24 Vaccinex, Inc. Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
MX2018012818A (es) 2016-04-22 2019-07-04 Vaccinex Inc Presentacion de proteina de membrana integral en viriones envueltos extracelulares de poxvirus.
IL264343B2 (en) 2016-08-02 2024-05-01 Vaccinex Inc Improved methods for generating polynucleotide libraries in cowpox/eukaryotic cells
SG11201906670PA (en) 2017-02-22 2019-08-27 Vaccinex Inc Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases

Also Published As

Publication number Publication date
PL3060252T3 (pl) 2020-05-18
CN106029093A (zh) 2016-10-12
EP3639853A1 (en) 2020-04-22
KR20160065981A (ko) 2016-06-09
US10385136B2 (en) 2019-08-20
KR102602502B1 (ko) 2023-11-14
KR20210118246A (ko) 2021-09-29
EP3060252A1 (en) 2016-08-31
DK3060252T3 (da) 2020-03-16
NZ630892A (en) 2016-03-31
AU2021202095A1 (en) 2021-05-06
US10800853B2 (en) 2020-10-13
AU2014340210A1 (en) 2016-05-05
CA2927841A1 (en) 2015-04-30
JP2019059786A (ja) 2019-04-18
KR20220110853A (ko) 2022-08-09
EA033072B1 (ru) 2019-08-30
WO2015061330A1 (en) 2015-04-30
MX2020009260A (es) 2020-10-01
EA201690813A1 (ru) 2016-08-31
PT3060252T (pt) 2020-03-04
IL275720A (en) 2020-08-31
AU2021202095B2 (en) 2023-11-02
US9598495B2 (en) 2017-03-21
IL245089A0 (en) 2016-06-30
CN106029093B (zh) 2023-03-28
US20170198053A1 (en) 2017-07-13
AU2021202095B9 (en) 2023-11-09
AU2019257379A1 (en) 2019-11-14
US20150110800A1 (en) 2015-04-23
SG11201603167YA (en) 2016-05-30
US20150353641A1 (en) 2015-12-10
ZA201602686B (en) 2020-11-25
JP6461944B2 (ja) 2019-01-30
CA3193983A1 (en) 2015-04-30
IL245089B (en) 2020-10-29
EP3060252B1 (en) 2019-12-11
IL295045B2 (en) 2024-04-01
IL275720B (en) 2022-09-01
IL295045A (en) 2022-09-01
US20190322757A1 (en) 2019-10-24
CA2927841C (en) 2023-05-23
US9249227B2 (en) 2016-02-02
AU2014340210B2 (en) 2019-08-08
JP6875363B2 (ja) 2021-05-26
EP3060252A4 (en) 2017-06-07
AU2019257379B2 (en) 2021-04-01
CN116966293A (zh) 2023-10-31
SG10201707786QA (en) 2017-10-30
BR112016009047B1 (pt) 2024-02-06
ES2773961T3 (es) 2020-07-15
KR102308493B1 (ko) 2021-10-07
IL295045B1 (en) 2023-12-01
JP2017502920A (ja) 2017-01-26
MX2016005050A (es) 2016-08-17
KR20230159633A (ko) 2023-11-21

Similar Documents

Publication Publication Date Title
BR112016009047A2 (pt) Uso de moléculas de ligação à semaforina-4d para tratar transtornos neurodegenerativos
BR112018071307A2 (pt) anticorpos agonistas que ligam cd40 humana e usos dos mesmos
BR112018010673A8 (pt) moléculas de anticorpo para april e seus usos
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
BR112016026993A2 (pt) combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
BR112018012138A2 (pt) moléculas de anticorpo para pd-1 e usos das mesmas
BR112017007379A2 (pt) moléculas de anticorpo para pd-l1 e usos das mesmas
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
BR112017005517A2 (pt) anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes
BR112017000671A2 (pt) moléculas com especificidade para cd79 e cd22
CY1119042T1 (el) Υποκατεστημενες ξανθινες και μεθοδοι χρησης αυτων
BR112016016436A2 (pt) moléculas de anticorpo para tim-3 e usos das mesmas
CL2013000459A1 (es) Anticuerpo aislado o fragmento que se enlaza a un estado inactivo de un receptor her; composicion farmaceutica que lo comprende; uso del anticuerpo para tratar cancer.
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
EA201490768A1 (ru) Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера
BR112016007112A2 (pt) Anticorpos que se ligam a angiopoietina 2 (ang-2) humana, usos de um anticorpo que se liga a angiopoietina 2 (ang-2) humana e combinação
BR112016001036A2 (pt) fusocinas envolvendo citocinas com afinidades de ligação de receptores fortemente reduzida
UA118083C2 (uk) ВИДІЛЕНЕ МОНОКЛОНАЛЬНЕ АНТИТІЛО ПРОТИ МОЛЕКУЛИ ВІДШТОВХУВАЛЬНОГО НАПРЯМНОГО СИГНАЛУ (RGMa) ТА ЙОГО ЗАСТОСУВАННЯ В ЛІКУВАННІ РОЗЛАДУ, АСОЦІЙОВАНОГО З ДЕГЕНЕРАЦІЄЮ НЕЙРИТІВ
EA201690728A1 (ru) Применение молекул, связывающих семафорин-4d, для лечения атеросклероза
BR112016014731A2 (pt) Anticorpos anti-baff
UY35493A (es) Métodos para el tratamiento de la osteogénesis imperfecta
BR112016002401A2 (pt) métodos para reduzir as taxas de exacerbação de asma usando benralizumab
BR112017025496A2 (pt) Moléculas de ligação neutralizantes anti- influenza e usos das mesmas
BR112015031710A2 (pt) anticorpos para o receptor de ldl oxidada similar à lectina 1 e métodos de uso
BR112018002319A2 (pt) anticorpos anti-cd154 e métodos de uso dos mesmos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B65X Notification of requirement for priority examination of patent application
B65Z Priority examination of the patent application refused (request does not comply with dec. 132/06 of 20061117)
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/10/2014, OBSERVADAS AS CONDICOES LEGAIS